





TEAR HERE

PLEASE FILL IN BLOCK LETTERS

TEAR HERE



COMMON APPLICATION FORM		VIJAYPD CEUTICAL LIMITED - INITIAL PUBLIC OFFER - NR Registered Office: A/1, 1st Floor, Devraj Premises, CHSL, Goregaon West, Mumbai - 400062, Maharashtra, India. Telephone: +91 9820917040; Email: investors@vijaypdceutical.com; Website: www.vijaypdceutical.com; Contact Person: Madhuri Ganesh Batwal, Company Secretary and Compliance Officer;		FOR NON-RESIDENTS, INCLUDING ELIGIBLE NRIs, FPIs AND REGISTERED MULTI LATERAL AND BILATERAL DEVELOPMENT FINANCIAL INSTITUTIONS ETC. APPLYING ON A REPATRIATION BASIS	
 To, The Board of Directors VIJAYPD CEUTICAL LIMITED CIN: U21001MH2024PLC421713		100% FIXED PRICE ISSUE ISIN : INE0WL901019		Application Form No.	
SYNDICATE MEMBER'S STAMP & CODE		REGISTERED BROKER / SCSB/ CDP/ RTA STAMP & CODE		1. NAME & CONTACT DETAILS OF SOLE / FIRST APPLICANT	
SCSBs BRANCH STAMP & CODE		SUB-BROKER'S/SUB-SYNDICATE'S/ SUB-AGENT'S STAMP & CODE		Mr./Ms./M/s.	
BANK BRANCH SERIAL NO.		REGISTRAR'S/SCSB SERIAL NO.		Address	
				Email	
				Tel. No. (with STD code) / Mobile	
				2. PAN OF SOLE / FIRST APPLICANT	
3. INVESTOR'S DEPOSITORY ACCOUNT DETAILS <input type="checkbox"/> NSDL <input type="checkbox"/> CDSL				6. INVESTOR STATUS (✓)	
For NSDL enter 8 digit DP ID followed by 8 digit Client ID / For CDSL enter 16 digit Client ID				<input type="checkbox"/> Non-Resident Indian(s) (Repatriation basis) - NRI	
4. APPLICATION DETAILS				<input type="checkbox"/> Registered Bilateral and Multilateral Development Financial Institutions - RBM	
				<input type="checkbox"/> Foreign Venture Capital Investor- FVCI	
				<input type="checkbox"/> Foreign Portfolio Investor - FPI	
				<input type="checkbox"/> All entities other than QIBs, Bodies Corporate and Individuals - NOH	
				<input type="checkbox"/> Others - OTH	
				5. CATEGORY (✓)	
				<input type="checkbox"/> Individual Applicant	
				<input type="checkbox"/> Non-Individual Applicant	
				<input type="checkbox"/> QIB	
Please note that applications must be made in minimum of 8,000 Equity Shares and further multiples of 4,000 Equity Shares accordingly.					
7. PAYMENT DETAILS [IN CAPITAL LETTERS] PAYMENT OPTION : FULL PAYMENT					
Amount blocked (₹ in figures) (₹ in words)					
ASBA Bank A/c No.					
Bank Name & Branch OR					
UPI Id (Maximum 45 characters)					
I/WE (ON BEHALF OF JOINT APPLICANTS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ AND UNDERSTOOD THE TERMS AND CONDITIONS OF THIS APPLICATION FORM AND THE ATTACHED ABRIDGED PROSPECTUS AND THE GENERAL INFORMATION DOCUMENT FOR INVESTING IN PUBLIC ISSUE AND HEREBY AGREE AND CONFIRM THE 'APPLICANT UNDERTAKING' AS GIVEN OVER LEAF. I/WE (ON BEHALF OF JOINT APPLICANTS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ THE INSTRUCTIONS FOR FILLING UP THE APPLICATION FORM GIVEN OVER LEAF.					
8A. SIGNATURE OF SOLE / FIRST APPLICANT		8B. SIGNATURE OF ASBA BANK ACCOUNT HOLDER(S) (AS PER BANK RECORDS)		Syndicate Members/ Sub-Indicate Member/ Registered Broker/ SCSB/ CDP/ RTA / AGENT STAMP (Acknowledging upload of Application in Stock Exchange system)	
Date: , 2025		I/We authorize the SCSB to do all acts as are necessary to make the Application in the Issue			
		1) 2) 3)			
----- TEAR HERE -----					
 VIJAYPD CEUTICAL LIMITED INITIAL PUBLIC OFFER - NR		Acknowledgement Slip for Syndicate Members/ Registered Broker/ SCSB/ CDP/ RTA / Agent		Application Form No.	
DPID / CLID		PAN of Sole / First Applicant			
Amount Blocked (₹ in figures)		ASBA Bank A/c No. / UPI ID		Stamp & Signature of SCSB Branch	
Bank Name & Branch					
Received from Mr./Ms./M/s.					
Telephone / Mobile		Email			
----- TEAR HERE -----					
VIJAYPD CEUTICAL LIMITED - INITIAL PUBLIC OFFER - NR		Stamp & Signature of Members of the Syndicate / Sub-Syndicate Member / Registered Broker / SCSB / CDP / RTA / Agent		Name of Sole / First Applicant	
Option 1 Option 2 Option 3					
No. of Equity Shares					
Issue Price (₹)					
Amount Blocked (₹ in figures)					
ASBA Bank A/c No. / UPI ID				Acknowledgement Slip for Applicant	
Bank Name & Branch				Application Form No.	
Important Note : Application made using third party UPI Id Or ASBA Bank A/c are liable to be rejected.					

**IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE PROSPECTUS
DATED SEPTEMBER 22, 2025. YOU ARE ENCOURAGED TO READ GREATER DETAILS AVAILABLE IN THE PROSPECTUS.**

APPLICANT'S UNDERTAKING FOR APPLICATION FORM

(IN CASE OF A JOINT APPLICATION, THE CONFIRMATIONS, AUTHORISATIONS, UNDERTAKINGS AND REPRESENTATIONS MADE BY THE FIRST APPLICANT WILL BE DEEMED TO HAVE BEEN MADE ON BEHALF OF ALL JOINT APPLICANTS. THE FIRST APPLICANT SHALL BE LIABLE FOR ALL THE OBLIGATIONS ARISING OUT OF THE ISSUE OF EQUITY SHARES.)

The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be issued or sold, and Application may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction. On the basis of the Prospectus dated September 22, 2025, filed with the Registrar of Companies, Mumbai, Maharashtra. I/We hereby confirm that I am/we are eligible person(s) to invest in the Issue in accordance with applicable laws. The amount payable on Application has been blocked in the ASBA Account with the relevant SCBS or the bank account linked with the UPI ID (in case of UPI Applicants using UPI Mechanism) as mentioned in this Application Form, as the case may be. I/We agree to accept the Equity Shares Applied for, or such lesser number as may be Allotted to me/us subject to the terms of the Prospectus, Abridged Prospectus, the GID, the Application Form and other applicable laws. I/We undertake that I/we will sign all such other documents and do all such acts, if any, necessary on my/our part to enable me/us to be registered as the holder(s) of the Equity Shares which may be Allotted and to register my/our address as given in the Depository records and to place my/our name on the register of members of the Company. I/We acknowledge that in case of QIB Applicants, only the SCBSs (for Applications other than the Applications by Anchor Investors), and the Lead Manager to Issue have the right to reject Applications (including on technical grounds) at the time of acceptance of Application Form provided that the reasons for rejecting the same shall be provided to such Applicant in writing, whereas it has a right to reject it from Non-Individual Applicant and Individual Investors/Applicant based only on technical grounds and/or as specified in the Abridged Prospectus, GID and the Prospectus as applicable. I/We authorise the Company to make the necessary changes in this Application Form for filing of the Prospectus with the RoC without intimation to me/us and use this Application Form as the application form for the purpose of the Issue. I/We confirm that I/we have read the Prospectus. My / our investment decision is solely based on the Prospectus.

I/WE CONFIRM THAT: EITHER I am/we are Indian national(s) resident in India and I am/we are not applying for the said Equity shares as nominees of any person resident outside India or foreign nationals or I am/we are Indian national(s) resident in India and I am/we are applying for the said Equity shares as power of attorney holder(s) of non-resident Indian(s) as mentioned on non-repatriation basis OR I am/we are Indian national(s) resident outside India and I am/we are applying for the said Equity shares on my/our own behalf through NRO account on non-repatriation basis. I/We represent, warrant, acknowledge and agree with the Company and the Lead Manager as follows: (A) I/We have read the Prospectus and that my/our investment decision is based solely on the Prospectus (B) I/We have read and agree to the representations, warranties and agreements contained the section "Other Regulatory and Statutory Disclosures-Disclaimer in respect of Jurisdiction" in the Prospectus (C) the Equity Shares issued in the Issue have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or the securities laws of any state of the United States and may not be issued or sold in the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable U.S. state securities laws and that the Equity Shares are being issued and sold only outside the United States in accordance with Regulation S under the Securities Act; (D) I was/were outside of the United States at the time the Issue of the Equity Shares was made to me/us and I am/we are outside the United States at the time I/we signed this Application Form; (E) the Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be issued or sold, and Application may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction; (F) I am/we are purchasing the Equity Shares pursuant to the laws of the jurisdictions applicable to me/us; (G) I am/we are not an affiliate of the Company or a person acting on behalf of such affiliate; (H) if I/we are making an application to acquire any of the Equity Shares as fiduciary or agent for one or more investor accounts, I/we have sole investment discretion with respect to each such account and I/we have full power to make the foregoing representations, warranties, acknowledgments and agreements on behalf of each such account; and (I) if I/we are making an application to acquire any of the Equity shares for one or more managed accounts, I am /we are authorized in writing by each such managed account to subscribe to the Equity shares for each such managed account and to make (and I/we hereby make) the representations, warranties, acknowledgments and agreements herein for and on behalf of each such account, reading the reference to "I/we" to include such accounts.

FOR QIB APPLICATION: We confirm that the Bid size/maximum Equity Shares applied for by us does not exceed the relevant regulatory approvals/limits. We are not prohibited from accessing capital markets under any order/ruling/judgment of any regulatory, judicial or any other authority, including Securities and Exchange Board of India ("SEBI") or under the provisions of any law, regulation or statute.

Further: (1) In accordance with ASBA process provided in the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations") and as disclosed in the RHP, I/we authorise (a) the Registered Brokers (at Broker Centres) or the SCBSs or the RTAs (at designated RTA Locations) or the CDPs (at Designated CDP Locations), as the case may be, to do all acts as are necessary to make the application in the Issue, including uploading our Application, blocking, unblocking of funds in the bank account of the applicant maintained with the SCBS as specified in the Application Form or in the bank account of the Applicant linked with the UPI ID provided in the Application Form, as the case may be, transfer of funds to the Public Issue Account on receipt of instruction from Registrar to the Issue or the Sponsor Bank, as the case may be, after finalisation of Basis of Allotment; and (b) the Registrar to the Issue or Sponsor Bank, as the case may be, to issue instruction to the SCBSs to unblock the funds in the specified bank account upon finalisation of the Basis of Allotment. 2) In case the amount available in the specified bank account is insufficient as per the highest Bid option, the SCBS/Registrar to the Issue shall reject the application. 3) I/We hereby authorise the Registered Brokers (at Broker Centres) or the SCBSs (at Designated SCBS Branches) or CDPs (at Designated CDP locations) or the RTAs (at Designated RTA locations), as the case may be, to make relevant revisions as may be required to be done in the Application, in the event of a revision. I/We hereby provide our consent to the Stock Exchanges / Sponsor Bank / NPCI / Registrar to the Issue for collecting, storing and usage validating our PAN details from the bank account where my / our amount is blocked by the relevant SCBSs.

I/We acknowledge that as per existing policy of the Government of India, OCBs cannot participate in the Issue. I am/We are not an OCB. For further details, see "Issue Procedure" and "Restriction on Foreign Ownership of Indian Securities" beginning on pages 303 and 325, respectively of the Prospectus.

INSTRUCTIONS FOR FILLING UP THE APPLICATION FORM

- Name of sole/first applicant should be exactly the same as it appears in the depository records. In case of joint Applications, only the name of the first Applicant (which should also be the first name in which the beneficiary accounts in held) should be provided in the Application Form. Application means an "indication to make an issue" and not as Issue.
- The first applicant, should mention his/her PAN allotted under the Income Tax Act, DP ID, Client ID and UPI ID as applicable except for applications by or on behalf of the Central or State Government and the officials appointed by the courts and by Applicants who are exempt from the requirement of obtaining/specifying their PAN for transacting in the securities market and by persons residing in Sikkim, the Applicants, or in the case of applications in joint names, the first applicant (the first name under which the beneficiary account is held), should mention his/her PAN allotted under the Income Tax Act. Any Application Form without the PAN is liable to be rejected other than as specified above. Investors must ensure that their PAN is linked with Aadhaar and are in compliance with Central Board of Direct Taxes ("CBDT") notification dated February 13, 2020 and press release dated June 25, 2021 and CBDT circular no.7 of 2022, dated March 30, 2022 read with press release dated March 28, 2023.
- Based on the PAN, DP ID, UPI ID (as applicable) and Client ID provided by the Applicants, the Registrar to Issue will obtain demographic details registered with depository participants to be used, among other things, for allotment, technical rejections, or unblocking of ASBA Account. Hence, Applicants are advised to immediately update any change in their demographic details as appearing on the records of the Depository to ensure accuracy of records. Please note that failure to do so could result in failure in allotment of Equity Shares, delays in unblocking of ASBA Account at the Applicants sole risk and neither the Syndicate or the Registrar to the Issue RTAs/CDPs or the SCBSs nor the company shall have any responsibility and undertake any liability for the same.
- Applications Lot and Price:** The Issue being 100% Fixed Price Issue at a Price of ₹ 35/- per Equity Shares has been decided by our Company in consultation with Lead Manager. The Face Value of Equity Shares ₹ 10/- each. Minimum Application Lot is 8,000 Equity Shares and in multiples of 4,000 Equity Shares thereafter. The Issue period shall be for a minimum of 3 Working Days and shall not exceed 10 Working Days. In case of revision of Price or force majeure, banking strike or similar circumstances, for reason to be recorded in writing, the Issue Period will be extended for at least three additional working days subject to the total Issue Period not exceeding 10 working days. Any revision in the Price and the revised Issue Period, if applicable will be widely disseminated by notification to Stock Exchange, by issuing a press release and also by indicating the changes on the website of the LM and Stock exchange.
- Maximum and Minimum Application Size:** For Individual Investors: Such number of Equity Shares in multiples of 4,000 Equity Shares so that the Application Amount shall be above two lots, accordingly, the minimum application size shall be above ₹2.00 Lakhs. For Other than Individual Investors: Such number of Equity Shares in multiples of 4,000 Equity Shares not exceeding the size of the Issue, subject to applicable limits to the Applicable Individuals Investors who applies for minimum application size: 2 lots such that the application size shall be above ₹ 2 lakhs in multiples of 4,000 Equity Shares. For Other than Individual Investors: Such number of Equity Shares in multiples of 4,000 Equity Shares of face value of ₹10/- each more than two lots.
- Please tick category as applicable to ensure proper upload of Application in Stock Exchange System.
- Please tick investor status as applicable. Please ensure investor status is updated in your depository records.
- The entire Issue price of ₹ 35/- per equity share is payable on application. In case of allotment of lesser number of equity shares than the number applied, the company shall unblock the excess amount paid on application to the applicants.
- Cheques/Demand Draft/Cash/stock investment/money orders/postal orders will not be accepted*. Eligible NRIs applying on a non-repatriation basis by using the Resident Application Form are required to authorise their SCBS to confirm or accept the UPI Mandate Request (in case of Individual Investors, applying through the UPI Mechanism), block their non-Resident Ordinary (NRO) Accounts for the full Application Amount, at the time of the submission of the Application Form. All Applications including the Eligible NRIs applying on a non-repatriation basis can obtain the Application Form from the Registered Office of the Company or from any of the Members of the Syndicate or CDPs or RTAs or Registered Brokers from the Application Centers. In accordance with applicable law and SEBI UPI Circulars, Applicants to please ensure that SCBS where the ASBA Account is maintained has notified at least one branch in the location where Application Forms will be deposited by Designated Intermediaries.
- Please note that application made using third party UPI Id or third party ASBA Bank A/c are liable to be rejected.
 - QIBs cannot use UPI Mechanism to apply. UPI Bidders applying up to Rs. 500,000 shall apply through UPI mode as per NPCI vide circular reference no. NPCI/UIP/OC No. 127/2021-22 dated December 09, 2021 read with SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/45 dated April 5, 2022.
 - For UPI Applicants applying using UPI Mechanism.**
 - Please ensure that your Bank is offering UPI facility for Public Issues.
 - Please mention UPI Id clearly in CAPITAL LETTERS only.
 - Ensure that the:** (a) bank where the bank account linked to their UPI ID is maintained; and (b) Applicants using the UPI Mechanism may apply through the SCBSs and mobile applications whose names appears on the website of the SEBI (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmlId=40>) and (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmlId=43>) respectively, as updated from time to time.
 - Eligible NRIs applying in the Issue through the UPI Mechanism, are advised to enquire with the relevant bank where their account is UPI linked prior to submitting their Application form.**
 - UPI Id cannot exceed 45 characters.**
 - Please ensure that you are using your UPI Id only and not the UPI of any third party.**
 - UPI Applicants using the UPI Mechanism shall ensure that details of the application are reviewed and verified by opening the attachment in the UPI Mandate Request and then proceed to authorise the UPI Mandate Request using his/her UPI PIN.** For further details, see "Issue Procedure" on page no. 303 of the Prospectus

- Only the first Applicant is required to sign the application form/ revision form. Thumb impressions and signatures other than in the languages specified in the Eighth Schedule to the Constitution of India must be attested by a Magistrate or a Notary Public or a Special Executive Magistrate under official seal. Signature of ASBA account holder is mandatory. If the first applicant is not account holder, ensure that the Application form is signed by the account holder. Necessary revisions in the Applicants undertaking and instructions will be required depending upon the jurisdiction in which the sale of shares is proposed.
- Other Instructions:** (a) Application must be made only in the prescribed Application Form. (b) Application must be completed in full, in BLOCK LETTERS in ENGLISH. Applicant should note that the Registered Brokers, CDPs, RTAs, and / or SCBSs will not be liable for errors in data entry due to incomplete or illegible Application Form. (c) Ensure that all applicable documents in support of Application are attached with the Application Form.
- The applicants may note that in case the DPID, Client ID and PAN mentioned in the Application Form and entered into the electronic biddings systems of the Stock Exchange do not match with the DP ID, Client ID and PAN available in the Depository database, the Application Form is liable to be rejected.
- The Equity Shares issued in the issue have not been and will not be registered under the U.S. Securities Act, 1933 ("Securities Act") or any state securities laws in the United States, and may not be issued or sold within the or to, or for the account or benefit of, "U.S. persons" (as defined in Regulation S of the Securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, United States. Accordingly, the Equity Shares will be issued and sold (i) in the United States only to "qualified institutional buyers", as defined in Rule 144A of the Securities Act, and (ii) outside the United States in offshore transactions in reliance on Regulation S under the Securities Act and in compliance with the applicable laws of the jurisdiction where those issues and sales occur.

The Company, Lead Manager or Banker to the Issue will provide the Prospectus either in physical form or electronic form or both as request made by you. You may not distribute or forward these documents and these documents are subject to the disclaimers and restrictions contained in or accompanying them. This Application Form is being issued to you on the basis that you (i) confirm that the representations, warranties, agreements and acknowledgement set out in Chapter titled "Other Regulatory and Statutory Disclosures" and "Issue Procedure" of the Prospectus and (ii) agree to abide by (1) this Application Form and (2) the Prospectus, together with the terms and conditions contained therein.

Note: Terms used but not defined therein shall have the meaning assigned to such terms in the Prospectus. For Detailed instructions for filling the various fields of this Application form, please refer to the General Information Document, which is available on the websites of the Lead Manager and Stock Exchange.

----- TEAR HERE -----

COMPANY CONTACT DETAILS		REGISTRAR TO ISSUE
VIJAYPD CEUTICAL LIMITED Registered Office: A/1, 1st Floor, Devraj Premises, CHSL, Goregaon West, Mumbai - 400062, Maharashtra, India. Telephone: +91 9820917040; Email: investors@vijaypdceutical.com; Website: www.vijaypdceutical.com; Contact Person: Madhuri Ganesh Batwal, Company Secretary and Compliance Officer		Kfin Technologies Limited Selenium Tower-B Plot No. 31 & 32 Gachibowli, Financial District, Nanakramguda Serilingampally, Hyderabad - 500032, Telangana, India Tel: +91 40 6716 2222 Email: vcl ipo@kfintech.com Website: www.kfintech.com Investor grievance e-mail: inward.ris@kfintech.com Contact person: M. Murali Krishna SEBI registration no.: INR000000221

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE PROSPECTUS



Please scan the QR Code to view the Prospectus)

This is an Abridged Prospectus containing salient features of the Prospectus dated September 22, 2025 ("Prospectus"). You are encouraged to read greater details available in the Prospectus which is available at <https://www.nseindia.com/companies-listing/raising-capital-public-issues-emerge-public-issue-offer-documents>

THIS ABRIDGED PROSPECTUS CONSISTS '8' PAGES. PLEASE ENSURE THAT YOU HAVE RECEIVED ALL THE PAGES



VIJAYPD CEUTICAL LIMITED

CIN: U21001MH2024PLC421713, Date of Incorporation: March 19, 2024

Registered Office	Corporate Office	Contact Person	Email and Telephone	Website
A/1, 1st Floor, Devraj Premises, CHSL, Goregaon West, Mumbai - 400062, Maharashtra, India.	N.A.	Madhuri Ganesh Batwal, Company Secretary & Compliance Officer	Email: investors@vijaypdceutical.com Telephone: +91 9820917040	www.vijaypdceutical.com

THE PROMOTERS OF OUR COMPANY ARE SAMIT MADHUKAR SHAH, BHAVIN DHIRENDRA SHAH, RAHUL JITENDRA SHAH, NARENDRA NAGINDAS SHAH, DINA MADHUKAR SHAH, VASANTI DHIRENDRA SHAH AND HEMANTI JITENDRA SHAH

DETAILS OF ISSUE TO PUBLIC:

Type of Issue (Fresh/ OFS/ Fresh & OFS)	Fresh Issue Size (by no. of shares or by amount in Rs.)	OFS Size	Total Issue Size	Issue Under 229(1)/ 229(2)	Share Reservation		
					QIB	NII	RII
Fresh Issue	55,00,000 Equity Shares aggregating to ₹ 1,925.00 Lakhs	NIL	55,00,000 Equity Shares aggregating to ₹ 1,925.00 Lakhs	229 (2)	NIL	26,08,000 Equity Shares	26,08,000 Equity Shares

These equity shares are proposed to be listed on the SME Platform of National Stock Exchange of India Limited ("NSE Emerge") and the Designated Stock Exchange will be the NSE.

DETAILS OF OFS BY PROMOTER(S)/ PROMOTER GROUP/ OTHER SELLING SHAREHOLDERS: N.A

Name	Type	No of Shares issued/ Amount in Rs.	WACA in Rs per Equity*
N.A.			

P: Promoter; PG: Promoter Group; OSS: Other Selling shareholder; WACA: Weighted Average Cost of Acquisition shall be calculated on fully diluted basis.

Issue Price, Minimum Bid Lot & Indicative Timelines	
Issue Price*	₹ 35/- per Equity Share of Face Value of ₹10/- Each
Minimum Bid Lot Size	4,000 equity shares.
Issue Open On	Monday, September 29, 2025
Issue Closes On	Wednesday, October 01, 2025
Finalisation of Basis of Allotment	On or before Friday, October 03, 2025
Initiation of Refunds	On or before Monday, October 06, 2025
Credit of Equity Shares to Demat accounts of Allottees	On or before Monday, October 06, 2025
Commencement of trading of Equity Shares	On or before Tuesday, October 07, 2025

*For details of Issue price and Basis for Issue Price, please refer to advertisement and page 103 of the Prospectus.

DETAILS OF WACA OF ALL SHARES TRANSACTED OVER THE TRAILING EIGHTEEN MONTHS FROM THE DATE OF THE PROSPECTUS:

Period	Weighted Average Cost of Acquisition (in Rs.)	Issue Price (₹ 35.00) being 'X' times of WACA
Trailing Eighteen Month from the date of Prospectus (Primary Acquisition)	19.74	1.77
Trailing Eighteen Month from the date of Prospectus (secondary Acquisition)	35.90	0.98
Weighted average cost of acquisition for past 5 primary issuances, as disclosed above	39.48	0.89
Weighted average cost of acquisition for past 5 secondary transactions, as disclosed above	27.97	1.25

As certified by M/s. JD Shah Associates, Chartered Accountants, by way of their certificate dated September 17, 2025.

WACA: Weighted Average Cost of Acquisition shall be calculated on fully diluted basis for not older than three years from the date of Prospectus.

RISKS IN RELATION TO THE FIRST ISSUE

This being the first public issue of our Company, there has been no formal market for the Equity Shares. The face value of the Equity Shares is ₹ 10/- each and the Issue Price is 3.5 times of the face value of the Equity Shares. The Issue Price (determined and justified by our Company in consultation with the Lead Manager as stated in "Basis for Issue Price" on page 103 of this Prospectus) should not be taken to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active or sustained trading in the Equity Shares or regarding the price at which the Equity Shares will be traded after listing.

GENERAL RISKS

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue, including the risks involved. The Equity Shares in the Issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of this Prospectus. Specific attention of the investors is invited to "Risk Factors" on page 31 of the Prospectus.

PROCEDURE

You may obtain a physical copy of the Application Form and the Prospectus from the Stock Exchange, Syndicate Members, Registrar to the Issue, Share Transfer Agents, Depository Participants, Stock Brokers, Underwriters, Bankers to the Issue, Investors' Associations or Self Certified Syndicate Banks.

If you wish to know about processes and procedures applicable to this issue, you may request for a copy of the Prospectus and/or the General Information Document (GID) from the Lead Manager or download it from the websites of the Stock Exchange i.e. www.nseindia.com and the LM at www.shcapl.com.

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE PROSPECTUS

Sr. No.	Issuer name	Issue size (₹ Crores)	Issue price (Rs.)	Listing Date	Opening price on Listing Date (in Rs.)	+/- % change in closing price, [+/- % change in closing benchmark] - 30 th calendar days from listing	+/- % change in closing price, [+/- % change in closing benchmark] - 90 th calendar days from listing	+/- % change in closing price, [+/- % change in closing benchmark] - 180 th calendar days from listing
Mainboard IPO Issues								
-	-	-	-	-	-	-	-	-
SME IPO Issues								
1.	Desco Infratech Limited	30.75	150.00	April 01, 2025	160.00	+62.47% [+5.55%]	+47.03% [+10.57%]	-
2.	Virtual Galaxy Infotech Limited	93.29	142.00	May 19, 2025	180.00	+22.15% [-0.37%]	+24.86% [-1.26%]	-
3.	Blue Water Logistics Limited	40.50	135.00	June 03, 2025	141.00	+13.52% [+3.71%]	+10.37% [-0.47%]	-
4.	Samay Project Services Limited	14.69	34.00	June 23, 2025	36.05	-2.06% [+0.36%]	-2.94% [+1.42%]	-
5.	AJC Jewel Manufacturers Limited	15.39	95.00	July 01, 2025	99.00	+4.42% [-2.65%]	-	-
6.	Chemkart India Limited	80.08	248.00	July 14, 2025	250.00	-12.48% [-2.45%]	-	-
7.	Umiya Mobile Limited	24.88	66.00	August 04, 2025	69.00	+6.06% [-1.06%]	-	-

Source: www.bseindia.com / www.nseindia.com

****All Issues disclosed above are SME IPO Issues. Disclosures subject to recent 7 issues (initial public offerings) in past financial year managed by Merchant Banker with common issues disclosed once.**

Name of Lead Manager and contact details (telephone and email id) of each LM	SMART HORIZON CAPITAL ADVISORS PRIVATE LIMITED (Formerly Known as Shreni Capital Advisors Private Limited) Telephone: 022-28706822 E-mail: director@shcapl.com
Name of Market Maker and contact details	SHRENI SHARES LIMITED (Formerly known as Shreni Shares Private Limited) Telephone: 022 2089 7022 E-mail: shrenisharespvtltd@yahoo.in
Name of Registrar to the Issue and contact details (telephone and email id)	KFIN TECHNOLOGIES LIMITED Telephone: +91 40 6716 2222 E-mail: vcl ipo@kfintech.com
Name of Statutory Auditor	M/s. J D Shah Associates, Chartered Accountant
Name of Credit Rating Agency and the rating or grading obtained, if any	NA
Name of Debenture trustee, if any	NA
Self-Certified Syndicate Banks	The list of SCSBs notified by SEBI for the ASBA process is available at www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes on the SEBI website, or at such other website as may be prescribed by SEBI from time to time. A list of the Designated Branches of the SCSBs with which an ASBA Applicant (other than an UPI Applicants using the UPI mechanism), not applying through Syndicate/Sub Syndicate or through a Registered Broker, may submit the ASBA Forms is available at www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=34 on the SEBI website, and at such other websites as may be prescribed by SEBI from time to time. Further, the branches of the SCSBs where the Designated Intermediaries could submit the ASBA Form(s) of Applicants (other than UPI Applicants) is provided on the website of SEBI at https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=35 which may be updated from time to time or at such other website as may be prescribed by SEBI from time to time.
Non-Syndicate Registered Brokers	You can submit Application Forms in the Issue to Registered Brokers at the Broker Centres. The list of the Registered Brokers, including details such as postal address, telephone number and e-mail address, is provided on the websites of the NSE at www.nseindia.com , as updated from time to time.
Details regarding website address(es)/ link(s) from which the investor can obtain list of registrars to Issue and share transfer agents, depository participants and stock brokers who can accept application from investor (as applicable)	The details of the Designated Registrar and Share Transfer Agents Locations and Designated Collecting Depository Participant Locations, along with their names and contact details are available on the website of the NSE at (www.nseindia.com) and updated from time to time.

PROMOTERS OF THE ISSUER COMPANY

Sr. No.	Name	Individual/ Corporate	Experience & Educational Qualification
1.	Samit Madhukar Shah	Individual	Samit Madhukar Shah aged 47 years, is the Chairman, and Managing Director of our company. He completed his Master of Business Administration Degree in Business Finance from University of Lincolnshire & Humberside in the year 2000. He collectively possesses more than 24 years of experience in the industry in which our company operates. His responsibilities include working closely with the Board of Directors to set and achieve strategic goals, ensuring that all departments operate in alignment with the company's mission and values. He plays an active role in high-level decision-making, focusing on guiding the company's expansion and diversification acquisition strategies. Additionally, he oversees the overall operations of the company, ensuring efficiency and regularly reviewing business processes to identify areas for improvement and implement necessary changes.

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE PROSPECTUS

2.	Bhavin Dhirendra Shah	Individual	Bhavin Dhirendra Shah aged 41 years, is the Whole Time Director of our Company. He holds a Bachelor Degree in Commerce from University of Mumbai in the year 2005. He collectively possesses more than 19 years of experience in the industry in which our company are operates. His responsibilities include contributing to the company's long-term vision, mission, and goals. He is actively involved in contributing to the development of the company's long-term vision, mission, and strategic goals. Additionally, he oversees the overall strategic and tactical implementation of distribution network and operational activities, ensuring the efficient and optimal delivery of pharmaceutical products.
3.	Rahul Jitendra Shah	Individual	Rahul Jitendra Shah aged 43 years, is the Whole Time Director of our Company. He completed his Master in Commerce from University of Mumbai in the year 2005. He has been associated with our company as Dispatch Manager of our company since May 01, 2001 and has an overall experience of 24 years. He is responsible for coordinating with various delivery partners, and managing all matters related to delivery and dispatch, including documentation, tracking shipments and maintaining inventory levels.
4.	Narendra Nagindas Shah	Individual	Narendra Nagindas Shah aged 70 years, is the Non-Executive Director of our Company. He holds secondary school examination certificate from Maharashtra State Board of Secondary Education Poona Divisional Board in the year 1970. He has been associated with our Company since incorporation as a founder member and has been instrumental in extensive R&D by conducting market research to assess the viability of the business ideas, pertaining to market demand, competition, relationship with customer & supplier, legal prospects and designing supply chain optimisation strategies. He was associated for 53 years with M/s. Vijay Pharma (Partnership Firm), prior conversion to our company.
5.	Dina Madhukar Shah	Individual	Dina Madhukar Shah , aged 75 years, is the Promoter and a Founding Member of our company. She resides at Karma Kshetra, D -1 Wing, 3 Floor, Flat No 34, Harbans Lal Marg, Sanmukhananda Hall King Circle, Sion East, Mumbai - 400037, Maharashtra, India. She completed her Pre-University Examination at Shreemati Nathibai Damodar Thackersey Women's University, Bombay, in 1967. While she was instrumental in the founding and growth of the company, she does not participate in the day-to-day operations and does not hold any industry experience
6.	Vasanti Dhirendra Shah	Individual	Vasanti Dhirendra Shah , aged 70 years is the Promoter of our Company. She resides at D9 - Duru Mahal, 2 nd Floor, 84, Shree Patan Jain Mandal Marg, Marine Drive, Kalbadevi, Mumbai - 400002, Maharashtra, India. While she was instrumental in the founding and growth of the company, she does not participate in the day-to-day operations and does not hold any industry experience.
7.	Hemanti Dhirendra Shah	Individual	Hemanti Dhirendra Shah , aged 70 years is the Promoter of our Company. She resides at D-1. Karmashetra, 15 Floor, Flat 154, Harbanslal Marg, Near Shanmukhanand Hall, Sion, Koliwada, Mumbai- 400037, Maharashtra, India. While she was instrumental in the founding and growth of the company, she does not participate in the day-to-day operations and does not hold any industry experience.

For details in respect of our Promoters, please see the section titled “Our Promoters and Promoter Group” beginning on page 195 of the Prospectus.

BUSINESS OVERVIEW AND STRATEGY

Company Overview: Our Company was originally formed as a partnership firm in 1971 and further converted into a public limited company. We are engaged in the business of distribution and supply within the pharmaceutical and consumer goods sectors, offering a comprehensive range of services. Our roles include being representatives, dealers, agents, stockists, suppliers, traders, and packers. We offer a wide range of products serving both the pharmaceutical and wellness industries, as well as the fastmoving consumer goods (FMCG) market. .

Products/ Service Offering: Our pharmaceutical and wellness product range includes medicines such as injections, tablets, capsules, ointments, suppositories, ophthalmic preparations, and liquid oral formulations. We also supply vitamins, hormones, enzymes, wellness tonics, serums, and diagnostic test kits. In the FMCG segment, we provide personal care and toiletry products, including soaps, sanitizers, and baby care items. Additionally, we deal in ayurvedic products, cosmetics, food products, dental products, and crude drugs.

Geographies Served: Our Company caters to Domestic Market.

Key Performance Indicators:

(Rs. In Lakhs)

Key Financial Performance	March 31, 2025	March 31, 2024	March 31, 2023
Financial KPIs			
Revenue from Operations	10,681.01	5,432.81	4,876.88
EBITDA	859.12	486.99	131.66
EBITDA Margin (%)	8.04%	8.96%	2.70%
PAT	479.55	165.02	18.16
PAT Margin (%)	4.49%	3.04%	0.37%
Return on equity (%)	28.91%	55.64%	3.96%
Debt-Equity Ratio (times)	0.68	30.04	5.18
Current Ratio (times)	1.90	0.95	0.57
Return on capital employed (%)	17.30%	14.61%	8.90%
Net fixed asset turnover ratio (times)	23.05	22.36	17.87
Operational KPIs			
Number of customers	2,109	1,295	1,205

Note: As certified by M/s. JD Shah & Associates, Chartered Accountants, by way of their certificate dated July 02, 2025.

Client Profile or Industries Served: Pharmaceuticals

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE PROSPECTUS

Revenue segmentation in terms of top 5/10 clients:

Based on Standalone Audited Financials:

(₹ in lakhs)

S. No	Particulars	For the year ended March 31, 2025		For the year ended March 31, 2024		For the year ended March 31, 2023	
		Amount	% of Revenue from Operations	Amount	% of Revenue from Operations	Amount	% of Revenue from Operations
1.	Top five customers	1,127.31	10.56%	563.02	10.37%	446.04	9.15%
2.	Top ten customers	1,827.42	17.11%	929.06	17.09%	775.37	15.92%

Note: As certified by M/s. JD Shah & Associates, Chartered Accountants, by way of their certificate dated June 30, 2025

Intellectual Property, if any: For details of Intellectual Property, please refer to page 167 of the Prospectus

Market Share: Not ascertainable

Manufacturing plant, if any: Since our Company deals in Distribution activity, this data is not available

Employee Strength: 51 Employees as on March 31, 2025

BOARD OF DIRECTORS

Sr No.	Name	Designation (Independent/ Whole time/ Executive/ Nominee)	Experience & Educational Qualification	Other Directorships
1.	Samit Madhukar Shah	Chairman & Managing Director	Samit Madhukar Shah aged 47 years, is the Chairman, and Managing Director of our company. He completed his Master of Business Administration Degree in Business Finance from University of Lincolnshire & Humberside in the year 2000. He collectively possesses more than 24 years of experience in the industry in which our company operates. His responsibilities include working closely with the Board of Directors to set and achieve strategic goals, ensuring that all departments operate in alignment with the company's mission and values. He plays an active role in high-level decision-making, focusing on guiding the company's expansion and diversification acquisition strategies. Additionally, he oversees the overall operations of the company, ensuring efficiency and regularly reviewing business processes to identify areas for improvement and implement necessary changes.	Companies • Saltiva Pharmaceuticals Private Limited • Revomed Private Limited
2.	Bhavin Dhirendra Shah	Whole-Time Director	Bhavin Dhirendra Shah aged 41 years, is the Whole Time Director of our Company. He holds a Bachelor Degree in Commerce from University of Mumbai in the year 2005. He collectively possesses more than 19 years of experience in the industry in which our company are operates. His responsibilities include contributing to the company's long-term vision, mission, and goals. He is actively involved in contributing to the development of the company's long-term vision, mission, and strategic goals. Additionally, he oversees the overall strategic and tactical implementation of distribution network and operational activities, ensuring the efficient and optimal delivery of pharmaceutical products.	Companies • Saltiva Pharmaceuticals Private Limited
3.	Rahul Jitendra Shah	Whole-Time Director	Rahul Jitendra Shah aged 43 years, is the Whole Time Director of our Company. He completed his Master in Commerce from University of Mumbai in the year 2005. He has been associated with our company as Dispatch Manager of our company since May 01, 2001 and has an overall experience of 24 years. He is responsible for coordinating with various delivery partners, and managing all matters related to delivery and dispatch, including documentation, tracking shipments and maintaining inventory levels.	Companies • Saltiva Pharmaceuticals Private Limited
4.	Narendra Nagindas Shah	Non-Executive Director	Narendra Nagindas Shah aged 70 years, is the Non-Executive Director of our Company. He holds secondary school examination certificate from Maharashtra State Board of Secondary Education Poona Divisional Board in the year 1970. He has been associated with our Company since incorporation as a founder member and has been instrumental in extensive R&D by conducting market research to assess the viability of the business ideas, pertaining to market demand, competition, relationship with customer & supplier, legal prospects and designing supply chain optimisation strategies. He was associated for 53 years with M/s. Vijay Pharma (Partnership Firm), prior conversion to our company.	Companies • Revomed Private Limited
5.	Nikita H Pedhdiya	Non-Executive Independent Director	Nikita H Pedhdiya aged 45 years is the Non-Executive Independent Director of our Company. She has completed her Bachelor of Commerce from University of Mumbai in the year 2001. She has completed her Bachelor of Laws from University of Mumbai in the year 2007. She obtained a Certificate of Practice from the Institute of Company Secretaries of India (ICSI) in the year 2015. She has more than 15 years of experience in the secretarial field secretarial and legal compliance, corporate governance, listing compliance. She has previously worked with Gujarat Foils Limited as Deputy Manager in the Secretarial & Legal Department, with Empire Mall Private Limited for two years, and with Choksi Imaging Limited for three years as Company Secretary. Since 2015, Ms. Pedhdiya has been practicing as a Company Secretary under her own firm, Nikita Pedhdiya & Associates, offering professional services in corporate governance, legal compliance, and secretarial matters.	NIL

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE PROSPECTUS

6.	Pulkit Gopal Prasad Agrawal	Non-Executive Independent Director	Pulkit Gopal Prasad Agrawal aged 30 years, is the Non-Executive Independent Director of our Company. He has completed his Bachelor of Commerce from University of Mumbai in the year 2015. He obtained a Certificate of Practice from the Institute of Chartered Accountants of India (ICAI) in 2017. In 2019, he completed the Certificate of Practical Training in Information Systems Audit from ICAI. In 2022, he received both the Certificate of Registration for Valuation of Securities and Financial Assets from the Insolvency and Bankruptcy Board of India (IBBI), and the Certificate of Membership from the ICAI Registered Valuers Organisation for the valuation of Securities and Financial Assets. He has an experience of more than 4 years in the field of finance, accountancy, valuation services, financial audits, and advisory roles. Currently he is associated as Partner at M/s. Singh Agrawal & Associates and ValuGenius Advisors LLP.	LLP • ValuGenius Advisors LLP
----	-----------------------------	------------------------------------	---	---

For the complete profile of our Board of Directors, please refer to the chapter title “Our Management” - Brief profile of our Directors beginning on page 181 of the Prospectus.

OBJECTS OF THE ISSUE

Details of means of finance -

The fund requirements for each of the objects of the issue are stated as follows:

(₹ In Lakhs)

Sr. No.	Object of the Issue	Amount proposed to be financed from Net Proceeds	Estimated Utilization of Net Proceeds in F.Y. 2025 - 2026	Estimated Utilization of Net Proceeds in F.Y. 2026 - 2027
1.	Funding of capital expenditure requirements of our company towards the construction of Pharmaceutical API/ Intermediates and Chemicals manufacturing plant and purchase of new machineries in MIDC – Shirampur, Ahmednagar, Maharashtra.	1,082.83	490.00	592.83
2.	Repayment/prepayment of all or certain of our borrowings availed of by our Company;	510.00	510.00	--
3.	General corporate purposes [#]	74.17	74.17	--
	Total	1,667.00	1074.17	592.83

[#]The amount to be utilised for general corporate purposes will not exceed fifteen percent of the amount being raised by our company or ₹ 10 Crores, whichever is less in accordance with Regulation 230(2) of the SEBI ICDR Regulation, 2018 as amended thereon.

Means of finance: The fund requirements for the Objects are proposed to be met entirely from the Net Proceeds, internal accruals, net worth and existing debt financing. Accordingly, we confirm that there is no requirement for us to make firm arrangements of finance through verifiable means towards at least 75% of the stated means of finance, excluding the amount to be raised through the Net Proceeds and existing identifiable internal accruals.

Details and reasons for non-deployment or delay in deployment of proceeds or changes in utilization of issue proceeds of past public issues / rights issue, if any, of the Company in the preceding 10 years: NA

Name of monitoring agency: NA

Terms of Issuance of Convertible Security, if any: NA

SHAREHOLDING PATTERN:

Sr. No.	Particulars	Pre-Issue number of Equity Shares	% Holding of Pre-Issue
1.	Promoters & Promoter Group	1,09,84,686	78.30%
2.	Public	30,44,000	21.70%
3.	Non - Promoter Non - Public	-	-
	Total	1,40,28,686	100.00%

NUMBER/AMOUNT OF EQUITY SHARES PROPOSED TO BE SOLD BY SELLING SHAREHOLDERS: NA

SUMMARY OF RESTATED FINANCIALS:

The following information has been derived from the Restated Financial Information:

(₹ in lakhs other than share data)

Particulars	For the period year ended March 31		
	2025	2024	2023
Equity Share capital/ Partners' Capital	1,402.87	100.00	493.15
Net worth	3,216.98	100.00	493.15
Total Income	10,758.53	5,433.94	5059.21
Restated profit/(loss) after tax	479.55	165.02	18.16
Earnings per share (Basic & diluted) (Post Bonus & Split) (₹)	3.84	8.25	0.91
Net Asset Value per Equity Share (Post Bonus & Split) (₹)	25.78	5.00	24.66
Total borrowings	2,177.29	3,003.87	2,556.39

For further details, see “Restated Financial Information” on page 203 of the Prospectus.

BUSINESS RISK FACTORS

The below mentioned risks are top 10 risk factors as per the Prospectus:

1. Our company is positioning itself to expand its market presence by diversifying into the manufacturing of Active Pharmaceutical Ingredients ("APIs"), which serve as raw materials for the formulation of various types of Finished Dosage Forms ("FDF") and Excipients. However, this expansion may expose us to several risks that could adversely affect our growth, prospects, cash flows, business operations, and financial condition.
2. We may incur losses, and our reputation may be adversely affected if customers return our products due to the distribution of expired, unsafe, defective, ineffective, or counterfeit products, as well as product spoilage, breakage, or damage during transportation or storage. Failure to comply with customer-prescribed quality standards may also result in loss of business. In addition, we may be subject to product liability claims.
3. We derive a significant portion of our revenue from customers located in Maharashtra. Any adverse developments in the region could adversely affect our business, results of operations, cash flows and financial condition.
4. Our Company is reliant on the demand from the pharmaceutical industry for a significant portion of our revenue. Any downturn in the pharmaceutical industry or an inability to increase or effectively manage our sales could have an adverse impact on our Company's business and results of operations.
5. Since our inception, we have completed one of the acquisitions of distributors in India to expand our business and increase our customer base and may continue to complete more acquisitions in the future. However, we may be unable to realize the anticipated benefits of past or future acquisitions successfully. Further, if we are unable to identify expansion opportunities or experience delays or other problems in implementing our strategy of inorganic growth, our business, financial condition, results of operations, cash flows and prospects may be adversely affected.
6. We procure a significant portion of our raw materials from suppliers based in the State of Maharashtra. Any adverse developments in the region could adversely affect our business, results of operations, cash flows and financial condition.
7. We do not have long term agreements with our customers, which could adversely impact our business as our customers can terminate their relationships with us without notice.
8. We do not have long-term agreements with manufacturer of pharmaceutical products and an increase in the cost of, or a shortfall in the availability or quality of such pharmaceutical products could have an adverse effect on our business, financial condition and results of operations.
9. We have experienced negative cash flows from operating activities in the past and may continue to experience negative cash flows in the future, which could adversely affect our business operations and financial condition.
10. We have not yet placed orders in relation to the funding Capital Expenditure towards purchase of plant and machinery which is proposed to be financed from the Issue proceeds of the IPO. In the event of any delay in placing the orders, or in the event the vendors are not able to provide the Plant and Machinery in a timely manner, or at all, may result in time and cost over-runs and our business, prospects and results of operations may be adversely affected. Our proposed Manufacturing Facility are subject to the risk of unanticipated delays in implementation due to factors including delays in construction, obtaining regulatory approvals in timely manner and cost overruns.

For further details, see "Risk Factors" on page 31 of the Prospectus.

SUMMARY OF OUTSTANDING LITIGATIONS, CLAIMS AND REGULATORY ACTION

A. Total number of outstanding litigations against our Company and amount involved:

Name of Entity	Criminal Proceedings	Tax Proceedings	Statutory or Regulatory Proceedings	Disciplinary actions by the SEBI or Stock Exchanges against our Promoters	Material Civil Litigations	Aggregate amount involved (Rs in Lakhs)
Company						
By the Company	NA	NA	NA	NA	NA	NA
Against the Company	NA	4	NA	NA	NA	45.08
Directors/KMPs/SMPs						
By our Directors	NA	NA	NA	NA	NA	NA
Against the Directors	NA	NA	NA	NA	NA	NA
Promoters*						
By Promoters	NA	NA	NA	NA	NA	NA
Against Promoters	NA	1	NA	NA	NA	0.25
Subsidiaries						
By Subsidiaries	NA	NA	NA	NA	NA	NA
Against Subsidiaries	NA	NA	NA	NA	NA	NA
Group Companies						
By Group Companies	NA	NA	NA	NA	NA	NA
Against Group Companies	NA	NA	NA	NA	NA	NA

*Our Promoters are also the director of the Company. Hence litigations against them have not been included under the heading of director to avoid repetition.

B. Brief details of top 5 material outstanding litigations against the company and amount involved: NA

C. Regulatory Action, if any - disciplinary action taken by SEBI or stock exchanges against the Promoters in last 5 financial years including outstanding action, if any: N.A.

D. Details of outstanding criminal proceedings against Promoters: - N.A

For further details of the outstanding litigation proceedings, see "Outstanding Litigation and Material Developments" on page 261 of the Prospectus.

ANY OTHER IMPORTANT INFORMATION AS PER LEAD MANAGER / ISSUER COMPANY - NA

DECLARATION BY THE COMPANY

We hereby declare that all relevant provisions of the Companies Act, 2013 and the guidelines or regulations issued by the Government and / or the guidelines or regulations issued by the Securities and Exchange Board of India, as the case may be, have been complied with and no statement made in this Prospectus is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts (Regulation) Rules, 1957, amended, or the rules made thereunder or Guidelines / Regulations issued, as the case may be. We further certify that all statements and disclosures made in this Prospectus are true and correct.

LIST OF SELF CERTIFIED SYNDICATE BANKS (SCSBs) UNDER THE ASBA PROCESS

Sr. No.	Name of the Bank	Controlling Branch & Address	Contact Person	Telephone Number	Fax Number	Email
1.	Axis Bank Ltd.	Centralised Collections and Payment Hub (CCPH) 5th Floor, Gigaplex, Building No. 1, Plot No. I.T.5, MIDC, Airoli Knowledge Park, Airoli, Navi Mumbai – 400708	Mr. Sunil Fadtare Assitant Vice President	022-71315906, 9819803730	022- 71315994	Sunil.fadtare@axisbank.com
2.	AU Small Finance Bank Limited	CP3 235, Industrial Area, Apparel Park, Mahal Road, Jagatpura, Jaipur, Rajasthan 302022	Vikrant Singh Sirohi	Mobile : +91 7340012357	-	cpcasba@aubank.in
3.	Bandhan Bank	Adventz Infinity@5, BN Block, Sector V, Salt Lake City, Kolkata	Sagar Ranjan Das Senior Manager	Mobile : 9022339164	-	asba.business@bandhanbank.com
4.	Bank of Baroda	Mumbai Main Office, 10/12 Mumbai Samachar Marg, Fort, Mumbai-23	Mr. Sonu A. Arekar	022-40468314, 40468307,	022-22835236	asba.fortap@bankofbaroda.com
5.	Bank of Maharashtra	Fort Branch, 1st Floor, Jammangal, 45/47, Mumbai Samachar Marg, Mumbai – 400023	SHRI. V R Kshirsagar (DGM)	022-22694160 22652595 22663947	022-22681296	brmrgr2@mahabank.co.in; bom2@mahabank.co.in
6.	BNP Paribas	BNP Paribas House, 1, North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai – 400051	Mr. Ashish. Chaturvedi, Mr. Dipu SA, Ms Prathima Madiwala	(022) 61964570/61964594/61964592	(022) 61964595	Ashish.chaturvedi@asia. bnpparibas.comdipu.sa@asia. bnpparibas.comprathima. madiwala@asia.bnpparibas.com
7.	Barclays Bank PLC	Barclays Bank PLC 601/603 Ceejay House, Shivsagar Estate, Dr Annie Besant Road, Worli, Mumbai – 400018	Parul Parmar	+91- 22 6719 6400/ 6575	+91- 22 6719 6996	Parul.parmar@barclays.com
8.	Bank of India	Phiroze Jeejeebhoy Tower, (New Stock Exchange Bldg), P. J. Tower, Dalal Street, Fort, Mumbai – 400 023.	Shri Navin Kumar Pathak, Senior Manager	022-22723631/1677/ 9619810717	022-22721782	Stockexchange.Mumbai, south@bankofindia.co.in
9.	Credit Suisse	10th Floor, Ceejay House, Plot F, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400018.	Yogesh Bachwani	098216 13306	-	yogesh.bachwani@credit-suisse.com
10.	CITI Bank NA	Citigroup Center, Plot No C-61, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051	S Girish	022-26535504, 98199 12248	022-26535824	s.girish@citi.com, asba.ops@citi.com
11.	Central Bank of India	Ground floor, Central Bank of India, Central Bank Building, Fort, Mumbai 400001	Mr. Vineet Bansaj	022- 22623148, 22623149	022-22623150	asba4082@centralbank.co.in
12.	Canara Bank	Canara Bank, Capital Market Service Branch,407, 4th floor, Himalaya House79, Mata Ramabai Ambedkar, Marg, MUMBAI-400 001	Mr. Arvind Namdev Pawar	022-22661618/ 22692973/ 9769303555	022-22664140	cb2422@canarabank.com, mbdcomcity@canarabank.com, hocmbd@canarabank.com
13.	City Union Bank Ltd.	48, Mahalakshmi St., T. Nagar, Chennai - 600 017.Tamil Nadu.	Sivaraman	044 - 24340010, 24343517, 24346060, 24348586, 9380286558, 9382642081	044 - 24348586	cub001@cityunionbank.com
14.	DBS Bank Ltd.	DBS Bank Ltd, Fort House, 221, Dr. D.N. Road, Fort, Mumbai, 400 001	Amol Natekar	+91 22 6613 1213	+91 22 6752 8470	amolnatekar@db.com
15.	DCB Bank	154, S.V.Patel Road, Dongri (E), Pin - 400009.	Meenaz Hasanali Thanawala	022-67474170	-	meenaz@dcbbank.com
16.	Dhanlaxmi Bank Limited	Ground Floor, Jannabhoomi Bhavan, Plot 11 -12, Jannabhoomi Marg, Fort Mumbai, Maharashtra – 400 001	Ramesh Menon	9167832288, 022- 22871658	-	ramesh.menon@dhanbank.co.in
17.	Deutsche Bank	Sidrah, 110, Swami Vivekananda Road, Khar (West), Mumbai 400052	Ms. Hetal Dholakia	(91) (022) 6600 9428 (91) (022) 6600 9419	-	hetal.dholakia@db.com manoj-s.naik@db.com; nanette. daryanani@db.com.
18.	Equitas Small Finance Bank	CPC, Phase II, 4th floor, Spencer Plaza, No 769, Anna Salai, Chennai - 600002	Chandrashekar Arumugam	(M) 8939886802	-	asbaoperations@equitasbank.com; asbarecon@equitasbank.com
19.	GP Parsik Sahakari Bank Limited	Shivram Patil Bhavan, Parsik Nagar, Kalwa, Thane	Mr.Mayur M.Tanksale	022-25456655	-	mmtanksale800@gpparsikbank.net / pjsbasba@gpparsikbank.net
20.	HSBC Ltd.	3rd Floor, PCM Dept. Umang, Plot CTS No. 1406-A/28, Mindspace, Malad (West) Mumbai 400 064 (address of IPO Operations office)	Mr Jagrut Joshi	(022) 67115485/ 9870403732	(022) 66536005	jagrutjoshi@hsbc.co.in
21.	HDFC Bank Ltd.	FIG – OPS Department HDFC Bank Ltd Lodha - I Think Techno CampusO-3 Level Next to Kanjurmarg Railway Station Kanjurmarg (East) Mumbai - 400042	Vincent Dsouza / Siddharth Jadhav / Prasanna Uchil	022-30752929 / 2927 / 2928	-	vincent.dsouza@hdfcbank.com, siddharth.jadhav@hdfcbank.com, prasanna.uchil@hdfcbank.com
22.	IDFC First Bank	Building no 2, Mindspace TTC Industrial Area, Juinagar. Navi Mumbai – 400 706	Mr. V M Praveen	022-49850025/ 9819708055	-	ASBA.CB@idfcfirstbank.com
23.	ICICI Bank Ltd.	ICICI BANK LIMITED, Capital Market Division, 1st Floor, 122, Mistry Bhavan, Dinshaw Vachha Road, Backbay Reclamation, Churchgate, Mumbai	Roshan Tellis	022-22859874/803	022-22611138	roshan.tellis@icicibank.com
24.	IDBI Bank Ltd.	IDBI Bank Limited Central Processing Unit, Sarju House, 3rd Floor, Plot No 7, Street No. 15, Andheri MIDC, Andheri (E), Mumbai.Pin : 400093	Shri. Naveen Nischal HP / Shri Viral Barodia	022- 66700525 / 685	-	hp.naveennischal@idbi.co.in / barodia.viral@idbi.co.in
25.	Indian Bank	Nandanam Branch- 480 Anna Salai, Nandanam 600035	Mr. V Muthukumar, Mr. M Veerabahu	044 24330233	044 24347755	nandanam@indianbank.co.in
26.	IndusInd Bank	IndusInd Bank Ltd. Fort Branch Sonawalla Bldg, Mumbai Samachar Marg, Fort, Mumbai 400001	Yogesh Adke Dy. Vice President	022-66366589 / 91 / 929833670809	022-22644834	yogesh.adke@indusind.com
27.	Indian Overseas Bank	Mexxanine Floor, Cathedral Branch, 762 Anna Salai, Chennai 600 002	Mr. V. Srinivasan	044 - 28513616	-	deposit@jobnet.co.in
28.	J P Morgan Chase Bank, N.A.	J.P. Morgan Tower, Off C.S.T. Road, Kalina Santacruz - East, Mumbai - 400 098	Mahesh Aras	022-61573811	022-61573949	Mahesh.aras@jpmorgan. comIndia.operations@jpmorgan.com
29.	Janata Sahakari Bank Ltd.	N S D L Department Bharat Bhavan, 1360, Shukrawar Peth, Pune -411002	Shri. Ajit Manohar Sane+91 9960239391	+91 (20) 24431011 +91 (20) 24431016 +91 9503058993	+91 (20) 24431014	jsbnsdl@dataone.in
30.	Karur Vysya Bank Ltd.	Demat Cell, Second Floor No 29, Rangan Street, T Nagar, Chennai - 600 017	Maruthi Kumar Yenamandra	044- 24340374	044-24340374	maruthikumar@kvbmail.com, kvbdp@kvbmail.com

Sr. No.	Name of the Bank	Controlling Branch & Address	Contact Person	Telephone Number	Fax Number	Email
31.	Karnataka Bank Ltd	The Karnataka Bank Ltd Mangalore-H O Complex Branch Mahaveera Circle Kankanady Mangalore - 575002	Ravindranath Baglodi [Sr.Manager]	Ph: 0824-2228139 /140 /141	Fax: 0824-2228138	Email: mlr.hocomplex@ktkbank.com
32.	Kotak Mahindra Bank Ltd.	Kotak Infinity, 6 th Floor, Building No. 21, Infinity Park, Off Western Express Highway, General AK Vaidya Marg, Malad(E)	Prashant Sawant	D-+91 22 6605 6959M-+91 9967636316	+91 66056642	prashant.sawant@kotak.com
33.	Mehsana Urban Co-Op. Bank Ltd.	Head Office, Urban Bank Road, Highway, Mehsana - 384002	Branch Manager	+91-2762-251908	+91-2762-240762	asba@mucbank.com
34.	Nutan Nagrik Sahakari Bank Ltd.	Opp Samratheshwar Mahadev, Nr. Law Garden, Ellisbridge, Ahmedabad-380006	Miti Shah	9879506795	7926564715	smiti@1977@yahoo.com
35.	Punjab National Bank	Capital Market Services Branch, PNB House, Fort, Sir P.M.Road Mumbai	Sh. K Kumar Raja	Tel - 022- 22621122, 22621123,	022 - 22621124	pncapsmumbai@pnb.co.in
36.	Punjab & Sind Bank	Rajindera Place- 21 Rajindra Place Bank House New Delhi-110008	RPS Sandhu	011- 25825784/25711836 9911129088	-	d0606@psb.co.in
37.	RBL Bank Limited	Techniplex - I, 9 th Floor, Off Veer Savarkar Flyover, Goregaon (West), Mumbai - 400062.	Shashikant Sanil	022-40288193, 022-40288196, 022-40288197	022-40288195	asba_ops@rblbank.com
38.	Rajkot Nagarik Sahakari Bank Ltd.	Nagrik Bhavan No 1 Parabazar Dhebarbhai Road Rajkot	Shri Yogesh Raveshiya	9427495222	(0281) 2233916/17/18	khumesh@rnsbindia.com; asba@rnsbindia.com
39.	State Bank of Hyderabad	Gunfoundry, Hyderabad	Sri Ashok Kulkarni	040-23387325	040-23387743	gunfoundry@sbyhd.co.in
40.	State Bank of Travencore	Anakatchery Buildings, Y M C A Road, Statue, Thiruvananthapuram-695001	P. P. Muraledharan	0471-2333676	0471-2338134	dptvm@sbt.co.in
41.	SVC Co-Operative Bank Ltd.	Unit No.601-602-603 Dosti Pinnacle Plot No. E-7, Road No.22, Wagle Estate, Thane 400604	Mr. Omkar Anil Sukhathankar	(O) 71991460 71991461 71991462 71991463 71991465	-	sukhathankaroa@svcbank.com
42.	State Bank of Bikaner & Jaipur	Financial Super Market Branch, Apex Mall, Tonk Road, Jaipur	Shri N K Chandak	0141-27444159413398505	0141-2744457	sbj11060@sbbj.co.in innkchandak@sbbj.co.in
43.	State Bank of India	State Bank of India, Capital Market Branch(11777),Videocon Heritage Building(Killick House),Charanjit Rai Marg, Fort, Mumbai - 400 001.	Ms. Raviti	Telephone:022-22094932 Mobile:9870498689	022-22094921	nib.11777@sbi.co.in
44.	Standard Chartered Bank	Crescenzo, 3rd Floor, C/38-39, G-Block, Opposite MCA Club, Bandra-Kurla Complex, Bandra [East], Mumbai 400-051	Rohan Ganpule	022 - 61157250 / 022 - 61157234	022 -26757358	lpo.scb@sc.com
45.	Syndicate Bank	Capital Market Service Branch, 26A, First Floor, Syndicate Building, P.M. Road, Fort, Mumbai.	P Padmavathy Sundaram, Chief Manager	022-22621844	022-22700997	padmas@syndicatebank.co.in/ cmsc@syndicatebank.co.in
46.	South Indian Bank	ASBA Cell (NODAL OFFICE) 2nd Floor, Shanu Towers, North Kalamassery, Ernakulam, Kerala - 683 104	John K Mechery	9645817905	0484-2351923	asba@sib.co.in
47.	State Bank of Patiala	CO 99-102, Sector - 8C, Chandigarh	Shri. Amarjit Singh Girm	0172-2779116, 2546124, 254386809779586096	0172-2546080	b5597@sbp.co.in
48.	State Bank of Mysore	P. B. No. 1066. # 24/28, Cama Building, Dalal Street, Fort, Mumbai -400 001	Shailendra kumar	7208048007022- 22678041	022-22656346	s.kumar@sbm.co.indalst@sbm.co.in
49.	The Federal Bank Limited	ASBA CELL, Retail Business Dept., Federal Bank, Marine Drive, Ernakulam 682031	Dhanya Dominic	0484-2201847	4842385605	rbd@federalbank.co.indhanyad@federalbank.co.inriyajacob@federalbank.co.in
50.	Tamilnad Mercantile Bank Ltd.	Tamilnad Mercantile Bank Ltd., Depository Participant Services Cell third Floor, Plot No.4923, Ac/16, 2nd Avenue, Anna Nagar (West), Chennai - 600 040, Tamilnadu, India	Mr. N. Rajasegaran	044-26192552	044-26204174	dps@tnmbonline.com
51.	The Jammu & Kashmir Bank Ltd.	79 A, Mehta House, Bombay Samachar Marg, Fort, Mumbai - 400 023.	Ashfaq Ahmad	9987984105, 022-66595971	022-6634183	bombay@jkbmail.com
52.	The Kalupur Commercial Co-Operative Bank Ltd.	Kalupur Bank Bhavan, Nr. Income Tax Circle, Ashram Road, Ahmedabad-380 014	Jay V. Pathak Manager	079-27582028	079-27544666	jay@kalupurbank.com
53.	The Lakshmi Vilas Bank Ltd.	Bharat House, Ground Floor, 104, Bombay Samachar Marg, Fort Mumbai - 400 001.	S Ramanan	022-22672255-22672247(M)- 22673435(CM)	022-22670267	Mumbai@fort_bm@lvbank.in
54.	The Surat Peoples Co-op Bank Ltd	Central Office. Vasudhara Bhavan, Timaliyawad, Nanpura, Surat - 395001	Mr. Iqbal Shaikh	0261-2464577	0261-2464577,592	Iqbal.shaikh@spcbl.in
55.	The Saraswat Co-operative Bank Ltd.	Madhushree, Plot No. 85, District Business Centre, Sector - 17, Vashi, Navi Mumbai - 400703	Mr. Ajit Babaji Satam	022-27884161 27884162 27884163 27884164	022-27884153	ab_satam@saraswatbank.com
56.	TJSB Sahakari Bank Ltd	2nd Floor, Madhukar Bhavan, Road No.16, Wagle Estate	Department Head	022-25838525/530/520		tjsbasba@tjsb.co.in
57.	Union Bank of India	MUMBAI SAMACHAR MARG,66/80, Mumbai Samachar Marg, Post Bag No.253 & 518, Fort, Mumbai - 400023.	Mr. D B JAISWAR	022-22629408	022- 22676685	jaiswar@unionbankofindia.com
58.	UCO Bank	Mumbai Main (Retail) Br., UCO Bank Bldg., D. N. Road, Mumbai- 400 023	Manager	022 40180117 9022457840	022-2222870754	bo.dnroad@mtnl.net.in
59.	Yes Bank Ltd.	YES Bank Limited, Indiabulls Finance Centre, Tower -II , 8th Floor, Senapati Bapat Marg, Elphinstone Road, Mumbai - 400 013.	Alok Srivastava / Shankar Vichare / Avinash Pawar	022 3347 7374/ 7259/ 7251	022 24214504	dlbtiservices@yesbank.in
60.	The Ahmedabad Mercantile Co-Op. Bank Ltd.	Head office - "Amco House", Nr. Stadium Circle, Navrangpura, Ahmedabad-09	Bimal P Chokshi	079-26426582-84-88	079-26564863	amcoasba@rediffmail.com
61.	Catholic Syrian Bank Ltd.	P B No. 1900, Ground Floor, Marshall Annex Building, Soorji Vallabhdas Marg, Ballard Estate, Mumbai, Maharashtra, Pin-400001	Ram Mohan G S	022-64502165, 022-22664269, 022-22665865, 022-22650850	-	mumbai@csb.co.in

ASBA Applicants may approach any of the above banks for submitting their application in the issue. For the complete list of SCSBs and their Designated Branches please refer to the website of SEBI <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=34>. A list of SCSBs is also displayed on the website of NSE at www.nseindia.com

**IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE PROSPECTUS
DATED SEPTEMBER 22, 2025. YOU ARE ENCOURAGED TO READ GREATER DETAILS AVAILABLE IN THE PROSPECTUS.**

APPLICANT'S UNDERTAKING FOR REVISION FORM

I/We (on behalf of joint applicants, if any) confirm that the Acknowledgement slip for my/our application are enclosed for the revisions which are being requested. I/we agree to be bound by all the terms & conditions mentioned in the Application Form submitted earlier by me/us.

I/We (on behalf of joint applicants, if any) authorize you to reject this Revision Form, in case any of the details of my existing Application as appearing on the electronic bidding system do not tally with the details in this Revision Form.

INSTRUCTIONS FOR FILLING UP THE REVISION FORM

- Name of sole/first applicant should be exactly the same as it appears in the depository records.
- Please ensure that the options provided are in the same order as that provided in the Application Form submitted earlier.
- In case there is no change in the particular application, please write "NO CHANGE". In case you want to cancel the application, please write "CANCELLED".
- Total amount payable must be calculated for the equity shares applied for at Issue Price. Total Application Amount to be paid must be calculated net of total amount paid at the time of submission of Application Form. Applicants, please ensure that your Bank has notified a SCSB Branch in the city where the Application Form is being submitted.
- Only the first Applicant is required to sign the application form/ revision form. Thumb impressions and signatures other than in the languages specified in the Eighth Schedule to the Constitution of India must be attested by a Magistrate or a Notary Public or a Special Executive Magistrate under official seal. Applicants should specify only his/her ASBA bank account or UPI ID linked with his/her own bank account in case of sole applicant and ASBA bank account or UPI ID linked with the bank account of First applicant in case of joint applicant, in the application form. If the First applicant is not the account holder, ensure that the Application Form is signed by the ASBA Account holder. Signature of the ASBA Account holder is mandatory.
- Please note that application made using third party UPI Id or ASBA Bank A/c are liable to be rejected.
 - QIBs cannot use UPI Mechanism to apply. UPI Applicants applying up to Rs. 500,000 can apply through UPI mode as per NPCI vide circular reference no. NPCI/UPI/OC No. 127/2021-22 dated December 09, 2021 read with SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/45 dated April 5, 2022.
 - For UPI Applicants applying using UPI Mechanism.**
 - Please ensure that your Bank is offering UPI facility for Public Issues.
 - Please mention UPI Id clearly in CAPITAL LETTERS only.
 - Ensure that the: (a) bank where the bank account linked to their UPI ID is maintained; and (b) Applicants using the UPI Mechanism may apply through the SCSBs and mobile applications whose names appears on the website of the SEBI (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmld=40>) and (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmld=43>) respectively, as updated from time to time.
 - Eligible NRIs applying in the Issue through the UPI Mechanism, are advised to enquire with the relevant bank where their account is UPI linked prior to submitting their Application Form.
 - UPI Id cannot exceed 45 characters.
 - Please ensure that you are using your UPI Id only and not the UPI of any third party.
 - Applicant using the UPI Mechanism shall ensure that details of the application are reviewed and verified by opening the attachment in the UPI Mandate Request and then proceed to authorize the UPI Mandate Request using his/her UPI PIN, For further details, see "Issue Procedure" on page no. 303 of the Prospectus.
- Other Instructions: a. Revision to Application must be made only in the prescribed Revision Form, as applicable. b. Application must be completed in full, in BLOCK LETTERS in ENGLISH. Applicants should note that the Syndicate Members/ SCSBs/Registered Brokers/ RTAs/ CDPs will not be liable for errors in data entry due to incomplete or illegible Revision Form. c. Ensure that Acknowledgement Slip for your application has and any other documents in support of the revision are attached with the Revision Form. d. Applicants shall only be required to issue instruction to block the revised amount in excess of their original blocked amount upon an upward revision of their Application

ISSUE STRUCTURE

Particulars	Market Maker Reservation Portion	Net Offer to Public
Number of Equity Shares available for allocation or allotment ⁽¹⁾	2,84,000 Equity Shares	52,16,000 Equity Shares
Percentage of Issue Size available for Allocation or allotment	5.16% of the Issue Size	94.84% of the Issue Size
Basis of Allotment	Firm allotment	Proportionate basis subject to minimum allotment of 2 Lots and further allotment in multiples of 4,000 Equity Shares. For details, see "Issue Procedure" beginning on page 303 of the Prospectus.
Mode of Application [^]	All the applicants shall make the application (Online or Physical) through the ASBA Process only (including UPI mechanism for Individual Investors (who applies for minimum application size) using Syndicate ASBA).	
Mode of Allotment	Compulsorily in dematerialised form	
Minimum Application Size	2,84,000 Equity Shares	<i>For Other than Individual Investors who applies for minimum application size:</i> Such number of Equity Shares in multiples of 4,000 Equity Shares of face value of ₹10/- each more than Two Lots. <i>For Individuals Investors who applies for minimum application size:</i> 2 Lots such that the application size shall be above ₹ 2.00 Lakhs in multiples of 4,000 Equity Shares.
Maximum Application Size	2,84,000 Equity Shares	<i>For Other than Individual Investors who applies for minimum application size:</i> Such number of Equity Shares in multiples of 4,000 Equity Shares not exceeding the size of the Issue, subject to applicable limits to the Applicant. <i>For Individuals Investors who applies for minimum application size:</i> Such number of Equity Shares in multiples of 4,000 Equity Shares so that the Application Amount shall be above Two Lots, accordingly, the minimum application size shall be above ₹ 2.00 Lakhs.
Trading Lot	4,000 Equity Shares, However the Market Maker may accept odd lots if any in the market as required under the SEBI ICDR Regulations	4,000 Equity Shares and in multiples thereof
Who can apply? ⁽²⁾	Market Maker	<i>For Other than Individual Investors who applies for minimum application size:</i> Resident Indian individuals, Eligible NRIs, HUFs (in the name of the Karta), companies, corporate bodies, scientific institutions societies and trusts. <i>For Individuals Investors who applies for minimum application size:</i> Resident Indian individuals, HUFs (in the name of the Karta) and Eligible NRIs.
Terms of Payment ⁽³⁾	The entire Application Amount will be payable at the time of submission of the Application Form.	
Application Lot Size	4,000 Equity Share and in multiples of 4,000 Equity Shares thereafter	

[^]SEBI vide its circular no. SEBI/HO/CFD/DIL2/P/CIR/2022/75 dated May 30, 2022, has mandated that ASBA applications in Public Issues shall be processed only after the application monies are blocked in the investor's bank accounts. Accordingly, Stock Exchange shall, for all categories of investors viz. NIs and IIs and other reserved categories and also for all modes through which the applications are processed, accept the ASBA applications in their electronic bidding platform only with a mandatory confirmation on the application monies blocked.

(1) Since present issue is a Fixed Price Issue, the allocation in the Net Issue to the public category in terms of Regulation 253 of the SEBI ICDR Regulations, as amended from time to time shall be made as follows:

- Minimum fifty percent to Individual Investors who applies for minimum application size; and
 - Remaining to:
 - Individual applicants who applies for more than minimum application size;
 - and other investors including corporate bodies or institutions, irrespective of the number of specified securities applied for;
- Provided that the unsubscribed portion in either of the categories specified in (a) or (b) above may be allocated to the applicants in the other category.


Explanation - For the purpose of sub-regulation (3), if the category of individual investors who applies for minimum application size is entitled to more than fifty per cent. of the issue size on a proportionate basis, such individual investors shall be allocated that higher percentage.

(2) In case of joint Applications, the Application Form should contain only the name of the first Applicant whose name should also appear as the first holder of the beneficiary account held in joint names. The signature of only such first Applicant would be required in the Application Form and such first Applicant would be deemed to have signed on behalf of the joint holders.

(3) In case of ASBA Applicants, the SCSB shall be authorised to block such funds in the bank account of the ASBA Applicant (including Individual Investors applying through UPI mechanism) that are specified in the Application Form. SCSBs applying in the Issue must apply through an ASBA Account maintained with any other SCSB.

----- TEAR HERE -----

	COMPANY CONTACT DETAILS	REGISTRAR CONTACT DETAILS
<ul style="list-style-type: none">In case of queries related to allotment/ credit of allotted equity shares, the Applicants should contact Registrar to the IssueIn case of Application submitted to the SCSBs, the Applicants should contact the relevant SCSBIn case of queries related to upload of Applications submitted to the RTAs/ Registered Brokers/CDPs, as applicable the Applicant should contact the relevant Designated Intermediary.For UPI related queries, investors can contact NPCI at the toll free number-18001201740 and Mail ld-ipo.upi@npciorg.in and the Registrar to the issue at Tel.: +91 40 6716 2222; and E-mail: vcl.ipo@kfintech.comIn case of ASBA Applicants (other than 3-in-1 Applications) for a bid above INR 5,00,000, ensure that the bid is uploaded only by the SCSBsEnsure that you have accepted the UPI Mandate Request received from the Sponsor Bank prior to 5:00 p.m. of the Issue Closing Date.	VIJAYPD CEUTICAL LIMITED Registered Office: A/1, 1st Floor, Devraj Premises, CHSL, Goregaon West, Mumbai – 400062, Maharashtra, India. Telephone: +91 9820917040; Email: investors@vijaypdceutical.com ; Website: www.vijaypdceutical.com ; Contact Person: Madhuri Ganesh Batwal, Company Secretary and Compliance Officer	Kfin Technologies Limited Selenium Tower-B Plot No. 31 & 32 Gachibowli, Financial District, Nanakramguda Serilingampally, Hyderabad - 500032, Telangana, India Tel: +91 40 6716 2222 Email: vcl.ipo@kfintech.com Website: www.kfintech.com Investor grievance e-mail: cinward.ris@kfintech.com Contact person: M. Murali Krishna SEBI registration no.: INR000000221



To,
The Board of Directors
VIJAYPD CEUTICAL LIMITED
CIN: U21001MH2024PLC421713

100% FIXED PRICE ISSUE
ISIN : INE0WL901019

Application Form No.

SYNDICATE MEMBER'S STAMP & CODE	REGISTERED BROKER / SCSB/ CDP/ RTA STAMP & CODE
SCSB BRANCH STAMP & CODE	SUB-BROKER'S/SUB-SYNDICATE'S/ SUB-AGENT'S STAMP & CODE
BANK BRANCH SERIAL NO.	REGISTRAR'S/SCSB SERIAL NO.

1. NAME & CONTACT DETAILS OF SOLE / FIRST APPLICANT
Mr./Ms./M/s. _____
Address _____
Email _____
Tel. No. (with STD code) / Mobile _____
2. PAN OF SOLE / FIRST APPLICANT _____
3. INVESTOR'S DEPOSITORY ACCOUNT DETAILS ☐ NSDL ☐ CDSL
For NSDL enter 8 digit DP ID followed by 8 digit Client ID / For CDSL enter 16 digit Client ID

PLEASE CHANGE MY APPLICATION

4. FROM (as per last Application or Revision)


Options	No. of Equity Shares applied (Application must be in multiples of 4,000 equity shares)							Price per Equity Share ₹ 35/- (In Figures)										
	(In Figures)							Application Price			Discount, if any			Net Price				
	7	6	5	4	3	2	1	3	2	1	4	3	2	1	4	3	2	1
Option 1																		
(OR) Option 2																		
(OR) Option 3																		

5. TO (Revised Application)

Options	No. of Equity Shares applied (Application must be in multiples of 4,000 equity shares)							Price per Equity Share ₹ 35/- (In Figures)										
	(In Figures)							Application Price			Discount, if any			Net Price				
	7	6	5	4	3	2	1	3	2	1	4	3	2	1	4	3	2	1
Option 1																		
(OR) Option 2																		
(OR) Option 3																		

6. PAYMENT DETAILS [IN CAPITAL LETTERS] **PAYMENT OPTION : FULL PAYMENT**
Amount blocked (₹ in figures) _____ (₹ in words) _____
ASBA Bank A/c No. _____
Bank Name & Branch _____
OR _____
UPI Id (Maximum 45 characters) _____
I/WE (ON BEHALF OF JOINT APPLICANTS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ AND UNDERSTOOD THE TERMS AND CONDITIONS OF THIS APPLICATION FORM AND THE ATTACHED ABRIDGED PROSPECTUS AND THE GENERAL INFORMATION DOCUMENT FOR INVESTING IN PUBLIC ISSUE AND HEREBY AGREE AND CONFIRM THE 'APPLICANT UNDERTAKING' AS GIVEN OVER LEAF I/WE (ON BEHALF OF JOINT APPLICANTS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ THE INSTRUCTIONS FOR FILLING UP THE APPLICATION FORM GIVEN OVER LEAF.

7A. SIGNATURE OF SOLE / FIRST APPLICANT Date: _____, 2025	7B. SIGNATURE OF ASBA BANK ACCOUNT HOLDER(S) (AS PER BANK RECORDS) I/We authorize the SCSB to do all acts as are necessary to make the Application in the Issue 1) _____ 2) _____ 3) _____	Syndicate Members/ Sub-Indicate Member/ Registered Broker/ SCSB/ CDP/ RTA/ AGENT STAMP (Acknowledging upload of Application in Stock Exchange system)



VIJAYPD CEUTICAL LIMITED
INITIAL PUBLIC OFFER - REVISION - NR

Acknowledgement Slip for Syndicate Members/ Registered Broker/ SCSB/ CDP/ RTA

Application Form No.

DPID / CLID _____

PAN of Sole / First Applicant _____

Additional Amount Blocked (₹ in figures) _____ ASBA Bank A/c. No./UP ID _____

Bank Name & Branch _____

Received from Mr./Ms./M/s. _____

Telephone / Mobile _____ Email _____

Stamp & Signature of Syndicate Members/ Sub-Indicate Member/Registered Broker/ SCSB / CDP/ RTA / Agent

Name of Sole / First Applicant _____

ASBA Bank A/c No. /UPI Id _____
Bank Name & Branch _____
Important Note : Application made using third party UPI Id Or ASBA Bank A/c are liable to be rejected.

Acknowledgement Slip for Applicant

Application Form No.